As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to apply to a newly established review board for approval. Once its treatment is rubber-stamped, the…

This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology. A fundamental flaw leaves LLMs strikingly vulnerable to attack  It is impossible to make large language models fully secure against hacks because of a fundamental flaw in how they work, a…